该研究成功构建了能够表达人源CD40分子（hCD40）的基因敲除小鼠模型（hCD40OST）。实验结果表明，hCD40OST小鼠B细胞表型和数量与野生型小鼠一致，并能正常活化；更进一步的研究发现，应用抗hCD40抗体后，hCD40OST小鼠的B细胞表 ...

The CD40/CD40 ligand (CD40L) costimulatory system, which amplifies immune responses and can induce inflammation, is believed to have a role in skin manifestations of other autoimmune diseases ...

The Business Research Company's CD40 Ligand CD40L Antibody Global Market Report 2025 – Market Size, Trends, And Forecast 2025-2034 Updated 2025 Market Reports Released: Trends, Forecasts to 2034 ...

Future studies are warranted to explore this pathway in GVHD prevention. The safety and preliminary activity observed in this initial study of CD40L blockade in the prevention of GVHD supports further ...

One such molecule is the CD40L, which engages CD40 on dendritic and B cells of the immune system, enabling T cells to become activated as a result. Rodent studies using coreceptor blockade with ...

Frexalimab is described by Sanofi as a ‘second-generation’ anti-CD40L antibody that can block the costimulatory CD40/CD40L cellular pathway necessary for adaptive and immune cell activation ...

Tonix Pharmaceuticals has reported positive topline outcomes from its Phase I single ascending dose study of its crystallisable fragment (Fc)-modified humanised anti-CD40 ligand (CD40L ...

The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.